The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
A settlement between the drugmaker and insulin patients that would have capped patients' out-of-pocket insulin costs at $35 for 4 years has fallen apart, after an "unfavorable ruling" from the judge overseeing the case.
In a recent speech, President Biden overstated the average monthly cost that patients were paying prior to the Inflation Reduction Act: The out-of-pocket cost for insulin was $58 for a 30-day supply, says a HHS report.
Novo Nordisk's list price for a monthly package of Ozempic is $935.77 before insurance and other rebates, yet it can be manufactured for between $0.89 to $4.73 a month, according to researchers at Yale University.
The average out-of-pocket cost for diabetes medications has increased by nearly 130% since 2018 – and those taking the newer GLP-1 drugs like Ozempic are feeling the increase the most, says a new GoodRx study.
"Finally, we beat Big Pharma," said President Joe Biden to U.S. Senator Bernie Sanders on Wednesday at a White House event to promote efforts to lower the cost of asthma inhalers and other health-care expenses.
Larry Krasner, Philadelphia's district attorney, filed a lawsuit against Eli Lilly, Novo Nordisk and other drugmakers and pharmacy benefit managers, on behalf of the 1.1 million Pennsylvanians who have diabetes, like himself.
The savings are not yet realized, says the Congressional Budget Office, which projects a 10-year cumulative savings of $161 billion from the phased-in drug negotiation, as well as a rebate for price increases above the inflation rate.
The $35 insulin cap reduces out-of-pocket costs for those with health savings accounts but new policies are needed to improve access to affordable insulin among commercially insured patients, says a new study.
The city of Baltimore, which paid more than $11 million in 2023 for diabetes medications through its self-funded plan, is suing the drug manufacturers, for allegedly conspiring to artificially hike the price of insulin.
Biden's policies on negotiating lower drug prices are in their early stages, but they are also starting to take effect for a number of drugs in the Medicare program.